A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)

Clinical Trial Grant

Duke Scholars

Principal Investigator Lake Daniel Morrison Medicine, Pulmonary, Allergy, and Critical Care Medicine

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Boehringer Ingelheim Pharmaceuticals, Inc.

Start Date

March 22, 2023

End Date

January 23, 2026

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Boehringer Ingelheim Pharmaceuticals, Inc.

Start Date

March 22, 2023

End Date

January 23, 2026